Back to search results

Long-Term Study of Afimkibart for Atopic Dermatitis

This study is looking at the long-term safety and how well Afimkibart (also known as RO7790121) works for people with Atopic Dermatitis (a chronic skin condition causing itchy and inflamed skin). You might be able to join if you are an adult (18 years or older) and have already participated in a previous clinical trial for Afimkibart (specifically, study CS45570). The main goal is to track any side effects over a long period, up to 6 years. This study is currently unclear about its recruitment status and plans to include about 120 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 120 participants.
What's involved
You would receive Afimkibart as a subcutaneous (under the skin) injection according to a set schedule. You would also complete assessments for how well the treatment works (EASI and IGA), quality of life (DLQI, POEM), and provide samples for safety and drug levels (PK).
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events (side effects) from the start of the study for up to 6 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07223697

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Recruiting
PHASE2Ages 18+InterventionalTreatment
Hoffmann-La Roche
~120 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:Afimkibart

At a glance

Recruiting sites
28 of 28 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants with Adverse Events
Measured over From Baseline up to 6 years

Conditions

Atopic Dermatitis

Explore related trials

Atopic Dermatitis

Where it's being run

28 sites across 17 states
Poland5
São Paulo4
Ontario4
Rio Grande do Sul2
California1
Florida1
Georgia1
Michigan1

Study leadership

  • Clinical Trials · STUDY_DIRECTOR · Hoffmann-La Roche

Who to contact

Reference Study ID Number: CS45943 https://forpatients.roche.com/ No attachments to email below.
[email protected]
888-662-6728 (U.S. Only)
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study
Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved =\> EASI50 response from study baseline

Exclusion

Evidence of other skin conditions that would interfere with the assessment of AD
Withdrawal of consent and/or premature discontinuation from parent study
Any permanent discontinuation of study drug in parent study
History of severe allergic reaction or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of Afimkibart

What this trial measures

  • Percentage of Participants with Adverse EventsFrom Baseline up to 6 years